Competitive intelligence on
small-molecule drugs and
the 80,000 global patents
covering them

Start your free trial now

No commitment — No credit card required

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: pegaptanib sodium

« Back to Dashboard

Summary for Generic Name: pegaptanib sodium

Tradenames:1
Patents:5
Applicants:1
NDAs:1
Drug Master File Entries: 0
Suppliers: see list1

Pharmacology for Ingredient: pegaptanib sodium

Clinical Trials for: pegaptanib sodium

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
Status: Terminated Condition: Cystoid Macular Edema

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Status: Completed Condition: Branch Retinal Vein Occlusion

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
Status: Completed Condition: Proliferative Diabetic Retinopathy; Diabetic Macular Edema

Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Status: Active, not recruiting Condition: Diabetic Macular Oedema

A Study On The Efficacy Of Macugen Injections In Patients With Neovascular Age-Related Macular Degeneration In Real Life.
Status: Completed Condition: Exudative Age-related Macular Degeneration

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Status: Active, not recruiting Condition: Proliferative Diabetic Retinopathy

Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema
Status: Completed Condition: Anti- VGF Inhibitor; Diabetic Macular Edema; Diabetic Retinopathy

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy
Status: Withdrawn Condition: Proliferative Diabetic Retinopathy

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Status: Completed Condition: Uveitis; Cystoid Macular Edema

A Pilot Study for the Treatment of Iris Neovascularization With Macugen
Status: Completed Condition: Iris Neovascularization; Diabetic Retinopathy

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756Dec 17, 2004RXYes6,011,020<disabled>Y<disabled>
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756Dec 17, 2004RXYes6,051,698<disabled>Y<disabled>
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756Dec 17, 2004RXYes5,919,455<disabled>Y<disabled>
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756Dec 17, 2004RXYes5,932,462<disabled>Y<disabled>
Valeant Pharms Llc
MACUGEN
pegaptanib sodium
INJECTABLE;INTRAVITREAL021756Dec 17, 2004RXYes6,113,906<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access , or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc